Literature DB >> 9029117

Protective monoclonal antibody defines a circumsporozoite-like glycoprotein exoantigen of Cryptosporidium parvum sporozoites and merozoites.

M W Riggs1, A L Stone, P A Yount, R C Langer, M J Arrowood, D L Bentley.   

Abstract

The apicomplexan protozoan parasite Cryptosporidium parvum causes a diarrheal disease in humans and other mammals for which specific therapy and immunoprophylaxis are unavailable. Passive immunization with Abs against whole C. parvum organisms has variable efficacy in immunocompromised or neonatal hosts. Because apical and surface-exposed zoite Ags of the Apicomplexa are critical to infectivity and targets of protective immunity, we examined the ability of mAbs generated against such Ags in C. parvum sporozoites to passively protect against infection and identify biologically relevant parasite molecules. A panel of mAbs was produced against affinity-purified native Ags using sporozoite apical- and surface-reactive mAb C4A1 as binding ligand. One resulting mAb, designated 3E2, elicited prominent morphologic changes in sporozoites and merozoites characterized by rapid and progressive formation, posterior movement, and release of membranous Ag-mAb precipitates. These changes had a striking resemblance to the malarial circumsporozoite precipitate (CSP) reaction. Sporozoite infectivity was completely neutralized after in vitro exposure to 3E2 and the CSP-like reaction. Furthermore, orally administered 3E2 completely prevented or markedly reduced infection in neonatal BALB/c mice. 3E2 bound to apical complex and surface molecules of zoites and was demonstrated in membranous precipitates by immunoelectron microscopy. In Western blots, 3E2 recognized multiple 46 to approximately 770 kDa sporozoite Ags and an approximately 1300-kDa Ag designated CSL, also expressed by merozoites. CSL was characterized as a soluble glycoprotein exoantigen released by infectious sporozoites. Further, CSL was determined to be the molecular species mechanistically involved in the CSP-like reaction by its identification in SDS-PAGE gels and Western blots of purified membranous precipitates. These findings indicate that CSL has a functional role in sporozoite infectivity and is a candidate molecular target for passive or active immunization against cryptosporidiosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9029117

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  27 in total

Review 1.  Back to the future: antibody-based strategies for the treatment of infectious diseases.

Authors:  H Barbaros Oral; Cüneyt Ozakin; Cezmi A Akdiş
Journal:  Mol Biotechnol       Date:  2002-07       Impact factor: 2.695

2.  Systemic and Mucosal Immune Responses to Cryptosporidium-Vaccine Development.

Authors:  Jacob G Ludington; Honorine D Ward
Journal:  Curr Trop Med Rep       Date:  2015-09-01

3.  Stable expression of Cryptosporidium parvum glycoprotein gp40/15 in Toxoplasma gondii.

Authors:  Roberta M O'Connor; Jane W Wanyiri; Boguslaw S Wojczyk; Kami Kim; Honorine Ward
Journal:  Mol Biochem Parasitol       Date:  2007-01-07       Impact factor: 1.759

4.  [(1)N,(12)N]Bis(Ethyl)-cis-6,7-dehydrospermine: a new drug for treatment and prevention of Cryptosporidium parvum infection of mice deficient in T-cell receptor alpha.

Authors:  W R Waters; B Frydman; L J Marton; A Valasinas; V K Reddy; J A Harp; M J Wannemuehler; N Yarlett
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

5.  Cyclosporin analogs inhibit in vitro growth of Cryptosporidium parvum.

Authors:  M E Perkins; T W Wu; S M Le Blancq
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

6.  Novel Bumped Kinase Inhibitors Are Safe and Effective Therapeutics in the Calf Clinical Model for Cryptosporidiosis.

Authors:  Deborah A Schaefer; Dana P Betzer; Kylie D Smith; Zachary G Millman; Hannah C Michalski; Sarah E Menchaca; Jennifer A Zambriski; Kayode K Ojo; Matthew A Hulverson; Samuel L M Arnold; Kasey L Rivas; Rama S R Vidadala; Wenlin Huang; Lynn K Barrett; Dustin J Maly; Erkang Fan; Wesley C Van Voorhis; Michael W Riggs
Journal:  J Infect Dis       Date:  2016-10-17       Impact factor: 5.226

7.  Cloning and sequence analysis of a highly polymorphic Cryptosporidium parvum gene encoding a 60-kilodalton glycoprotein and characterization of its 15- and 45-kilodalton zoite surface antigen products.

Authors:  W B Strong; J Gut; R G Nelson
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

8.  Molecular cloning and expression of a gene encoding Cryptosporidium parvum glycoproteins gp40 and gp15.

Authors:  A M Cevallos; X Zhang; M K Waldor; S Jaison; X Zhou; S Tzipori; M R Neutra; H D Ward
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

9.  Role of immunoglobulin A monoclonal antibodies against P23 in controlling murine Cryptosporidium parvum infection.

Authors:  F J Enriquez; M W Riggs
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

10.  Antibodies fused to innate immune molecules reduce initiation of Cryptosporidium parvum infection in mice.

Authors:  Michael Imboden; Michael W Riggs; Deborah A Schaefer; E Jane Homan; Robert D Bremel
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.